Latest HAL publications
- [hal-05442171] Machine Learning for the Prediction of Size and Encapsulation Efficiency of mRNA-Loaded Lipid Nanoparticles...by ano.nymous@ccsd.cnrs.fr.invalid (Joanna Duffrène) on 7 April 2026
Lipid nanoparticles (LNPs) have gained significant attention thanks to their ability to encapsulate and deliver mRNA. Exploring a variety of lipid compositions and different preparation processes is essential for a better understanding of the mRNA […]
- [hal-05579637] First preclinical evaluation of a thermogel delivering mitomycin C: sustained local release with preserved...by ano.nymous@ccsd.cnrs.fr.invalid (Christian Mouawad) on 3 April 2026
Background Peritoneal recurrence remains a major concern in colorectal cancer surgery. We aimed to evaluate the safety and preliminary efficacy of a novel poloxamer-based thermogel delivering Mitomycin C (TGel-MMC) as a simple prophylactic approach […]
- [hal-05568751] Grafted-cerium oxide nanoparticles with PEG polymers and DNase for improved ischemic stroke treatmentby ano.nymous@ccsd.cnrs.fr.invalid (Braham Mezghrani) on 26 March 2026
[...]
- [hal-05568624] Functionalization of antioxidant cerium oxide nanoparticles with DNase I to improve ischemic stroke treatmentby ano.nymous@ccsd.cnrs.fr.invalid (Norhane Salah) on 26 March 2026
[...]
- [hal-05568554] Functionalization of antioxidant Cerium Oxide Nanoparticles with DNase I for improving ischemic stroke treatment.by ano.nymous@ccsd.cnrs.fr.invalid (Md Nasir Arafath) on 26 March 2026
[...]
- [hal-05568464] Functionalization of antioxidant cerium oxide nanoparticles with DNase I to improve ischemic stroke treatment.by ano.nymous@ccsd.cnrs.fr.invalid (Norhane Salah) on 26 March 2026
[...]
- [hal-05498323] DNase I-Conjugated Cerium Oxide Nanoparticle-Based Treatment to Improve Thrombolysisby ano.nymous@ccsd.cnrs.fr.invalid (Md Nasir Arafath) on 7 February 2026
Ischemic stroke, caused by the occlusion of a cerebral artery by a thrombus, remains a major global health concern. While recombinant tissue plasminogen activator (rtPA) is the only approved pharmacological treatment for thrombolysis, its limited […]
- [hal-05399480] Color-Tunable Persistent Luminescence in Eu 2+ ,Dy 3+ ,B 3+ co-doped Sr 4 Al 14 O 25 and SrAl 2 O 4 Strontium...by ano.nymous@ccsd.cnrs.fr.invalid (Guanyu Cai) on 5 December 2025
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Persistent luminescent (PersL) materials have garnered significant attention for applications in signaling, bioimaging, and anti-counterfeiting due to their long lasting emission after […]
- [hal-05390034] Characterization and quantification of therapeutic monoclonal antibodies, anti-drug antibodies and their...by ano.nymous@ccsd.cnrs.fr.invalid (Lola Alez-Martin) on 3 December 2025
Therapeutic monoclonal antibodies (mAbs) are experiencing tremendous developments in terms of novel approved products and applications fields. Nonetheless, after administration, mAbs are submitted to a significant number of biological phenomena that […]
- [hal-05393790] A colorimetric supramolecular sensor array for anaesthetic drugs detection and classificationby ano.nymous@ccsd.cnrs.fr.invalid (Carlos Gonzalez-Galindo) on 2 December 2025
The global pharmaceutical industry has experienced significant growth, accompanied by a worrying increase in counterfeit medicines. Substandard medicines pose serious health risks, including poisoning, exacerbation of untreated conditions and […]
- [hal-05392740] ZGSO:Cr 3+ ,Ni 2+ Persistent Phosphors with Dual Emission in NIR‐I and SWIR Ranges for Bio‐Imaging Applicationsby ano.nymous@ccsd.cnrs.fr.invalid (Guanyu Cai) on 2 December 2025
Persistent luminescence (PersL) is widely used for near infrared (NIR‐I, 650–950 nm) imaging as they allow getting images without background. Bio‐imaging in the second shortwave‐infrared region SWIR‐II (NIR‐II, 1000–1400 nm) is less […]
- [tel-05381306] Nanoformulations d'agents antioxydants à visée ophtalmique pour la prévention de la dégénérescence maculaire...by ano.nymous@ccsd.cnrs.fr.invalid (Mitta Pierre) on 25 November 2025
Introduction : la dégénérescence maculaire liée à l'âge (DMLA) est une maladie rétinienne cécitante où la dysrégulation du stress oxydatif joue un rôle majeur. L'étude AREDS (Age-Related Eye Disease Study), vaste essai clinique […]